Investor Relations

Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.

Presentations

Financial Information

Press Releases

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

May 24, 2021

- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy , PhD, Head of Biotechnology Research at Maxim Group - AUSTIN, Texas , May 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

May 12, 2021

- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - AUSTIN, Texas , May 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it

View all